Enveric Biosciences, Inc. (ENVB)
- Previous Close
1.2800 - Open
1.2700 - Bid 0.9504 x 200
- Ask 1.5600 x 200
- Day's Range
1.2105 - 1.3497 - 52 Week Range
1.0100 - 193.5000 - Volume
2,192,960 - Avg. Volume
2,641,469 - Market Cap (intraday)
3.213M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-19.0400 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Apr 23, 2008
- 1y Target Est
10.00
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company is headquartered in Naples, Florida.
www.enveric.comRecent News: ENVB
View MorePerformance Overview: ENVB
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENVB
View MoreValuation Measures
Market Cap
3.11M
Enterprise Value
-3.96M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.96
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-83.70%
Return on Equity (ttm)
-178.91%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-9.3M
Diluted EPS (ttm)
-19.0400
Balance Sheet and Cash Flow
Total Cash (mrq)
4.29M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.78M